The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine
- PMID: 11229514
- PMCID: PMC1906906
- DOI: 10.1016/S1525-1578(10)60625-3
The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine
Abstract
The purpose of this study was to develop a multitarget, multicolor fluorescence in situ hybridization (FISH) assay for the detection of urothelial carcinoma (UC) in urine specimens. Urinary cells obtained from voided urine specimens of 21 patients with UC and 9 normal donors were analyzed with nine different centromere enumeration probes and a single locus-specific indicator probe to determine an optimal set of FISH probes for UC detection. The four probes with the greatest sensitivity for UC detection were then labeled with a unique fluorophore and combined into a single probe set. The probes with the greatest combined sensitivity for UC detection were CEP3, CEP7, CEP17, and the 9p21 (P16) LSI. This probe set was used to evaluate urine specimens acquired from 179 patients for prospective testing (46 with biopsy-proven UC). FISH slides were evaluated by scanning the slide for cells with nuclear features suggestive of malignancy and assessing the FISH signal pattern of these cells for polysomy (ie, gains of two or more different chromosomes). A receiver operator characteristic curve revealed that a cutoff of 5 cells with polysomy as the positive criterion for cancer resulted in an overall sensitivity of 84.2% for patients with biopsy-proven UC and a specificity of 91.8% among patients with genitourinary disorders but no evidence of UC. This study demonstrates that a multitarget, multicolor FISH assay containing centromeric probes to chromosomes 3, 7, and 17 and a locus-specific probe to band 9p21 has high sensitivity and specificity for the detection of UC in voided urine specimens.
Figures



Similar articles
-
[Numerical aberrations of chromosomes 11 and 17 detected by fish--fluorescence in situ hybridization combined with cytology in exfoliated cells from voided urine in patients with urothelial carcinoma of the bladder].Harefuah. 2007 Dec;146(12):914-9, 1000. Harefuah. 2007. PMID: 18254439 Hebrew.
-
Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology.J Urol. 2003 Jun;169(6):2101-5. doi: 10.1097/01.ju.0000066842.45464.cc. J Urol. 2003. PMID: 12771727
-
Utility of a multiprobe fluorescence in situ hybridization assay in the detection of superficial urothelial bladder cancer.Cancer Genet Cytogenet. 2007 Mar;173(2):131-5. doi: 10.1016/j.cancergencyto.2006.10.011. Cancer Genet Cytogenet. 2007. PMID: 17321328
-
Bladder cancer detection using FISH (UroVysion assay).Adv Anat Pathol. 2008 Sep;15(5):279-86. doi: 10.1097/PAP.0b013e3181832320. Adv Anat Pathol. 2008. PMID: 18724101 Review.
-
UroVysion® multiprobe FISH in the triage of equivocal urinary cytology cases.Ann Pathol. 2012 Dec;32(6):e52-6, 438-43. doi: 10.1016/j.annpat.2012.09.207. Epub 2012 Nov 24. Ann Pathol. 2012. PMID: 23244486 Review. English, French.
Cited by
-
Addition of Chromosome 17 Polysomy and HER2 Amplification Status Improves the Accuracy of Clinicopathological Factor-Based Progression Risk Stratification and Tumor Grading of Non-Muscle-Invasive Bladder Cancer.Cancers (Basel). 2022 Sep 21;14(19):4570. doi: 10.3390/cancers14194570. Cancers (Basel). 2022. PMID: 36230493 Free PMC article.
-
Targeting bladder tumor cells in voided urine of Chinese patients with FITC-CSNRDARRC peptide ligand.Onco Targets Ther. 2012;5:85-90. doi: 10.2147/OTT.S31368. Epub 2012 May 7. Onco Targets Ther. 2012. PMID: 22623877 Free PMC article.
-
Micropapillary urothelial carcinoma: Cytologic features in a retrospective series of urine specimens.Cytojournal. 2013 Feb 28;10:4. doi: 10.4103/1742-6413.107986. Print 2013. Cytojournal. 2013. PMID: 23599723 Free PMC article.
-
Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses.Am J Pathol. 2002 Aug;161(2):413-20. doi: 10.1016/S0002-9440(10)64197-1. Am J Pathol. 2002. PMID: 12163366 Free PMC article.
-
Urine-based assays for the detection of bladder cancer.Biomark Med. 2009 Jun 1;3(3):265. doi: 10.2217/bmm.09.23. Biomark Med. 2009. PMID: 20161673 Free PMC article.
References
-
- Messing EM, Catalona W: Urothelial tumors of the urinary tract. Walsh PC Retik AB Darracott Vaughan E Wein AJ eds. Campbell’s Urology 7th ed. 1998:2327-2410 W.B. Saunders Company Philadelphia
-
- Fitzgerald JM, Ramchurren N, Rieger K, Levesque P, Silverman M, Libertino JA, Summerhayes IC: Identification of H-ras mutations in urine sediments complements cytology in the detection of bladder tumors. J Natl Cancer Inst 1995, 87:129-133 - PubMed
-
- Schmetter BS, Habicht KK, Lamm DL, Morales A, Bander NH, Grossman HB, Hanna MGJ, Silberman SR, Butman BT: A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. J Urol 1997, 158:801-805 - PubMed
-
- Thomas L, Leyh H, Marberger M, Bombardieri E, Bassi P, Pagano F, Pansadoro V, Sternberg CN, Boccon-Gibod L, Ravery V, Le Guludec D, Meulemans A, Conort P, Ishak L: Multicenter trial of the quantitative BTA-TRAK assay in the detectin of bladder cancer. Clin Chem 1999, 45:472-477 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous